Wilmington PharmaTech Secures Major Investment to Accelerate Expansion
A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.
U.S. CRDMO, Wilmington PharmaTech, has announced that private equity firm, Curewell Capital, has taken a majority equity stake in the company (1). The injection of growth capital will enable Wilmington PharmaTech to significantly scale up its manufacturing output, support investments in new technologies, and broaden the company’s service offerings to cover the entire drug development lifecycle for small molecule APIs.
Wilmington PharmaTech’s founder and CEO, Dr. Hui-Yin "Harry" Li, will maintain a significant ownership stake and remain actively involved in leading the company’s day-to-day operations alongside the management team.
Wilmington’s main operations are located on a state-of-the-art, 54-acre campus in Newark, Delaware that features two modern production facilities equipped with comprehensive current good manufacturing practice (CGMP) capabilities. Within the campus, dedicated areas for high-potency APIs (HPAPI) and antibody-drug conjugates (ADCs) are supported by advanced analytical and scale-up laboratories designed to ensure seamless process transfer. Its campus includes greenfield sites reserved for future expansion into biologics production, offering strategic opportunities for Wilmington to increase its manufacturing output and broaden its service capabilities with the funding.
By increasing production capacity and capabilities, Wilmington PharmaTech will strengthen its position as a strategic partner for biopharma firms interested in localizing manufacturing in the U.S. amidst growing demand for local innovation, promising accelerated drug development and commercialization timelines.
“Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies, and we are committed to further expanding our capabilities and capacity to better serve our global biopharmaceutical partners,” said Li in a company press release (1).
“We are thrilled to partner with Dr. Li and his outstanding team, who have built an exceptional organization with deep scientific expertise and a strong reputation for excellence within the pharma science community,” added Michael Dal Bello, Partner at Curewell Capital in the press release (1). “Our investment will help WPT accelerate its next phase of growth amid strong market demand for specialized development capabilities and dependable, high-quality manufacturing capacity in the U.S (1).”
Founded in 2003, Wilmington PharmaTech has become a trusted, scientifically driven partner for pharmaceutical and biotechnology companies worldwide, supporting its clients throughout the entire drug development process, from early discovery and clinical trials to commercial launch. The company offers custom solutions for small molecule API development, drawing on expertise in complex synthesis, medicinal chemistry, process research and development, and CGMP manufacturing.
Curewell Capital is a growth-oriented private equity firm headquartered in Los Angeles, dedicated to building industry-leading healthcare companies across North America, with an investment thesis centered on partnering with founder-led organizations that enhance patient outcomes and foster innovation. Led by a team of experienced investors, Curewell focuses on scaling mid-size healthcare businesses through strategic investment and operational expertise spanning health tech, medtech, and pharmaceutical services.
Reference
BusinessWire.Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital. Press Release, Oct. 21, 2025.